Black Diamond Therapeutics Inc
BDTX2.255USD
+0.095+4.40%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
128.41MValor de mercado
5.95P/L TTM
Mais detalhes de Black Diamond Therapeutics Inc Empresa
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Informações de Black Diamond Therapeutics Inc
Código da empresaBDTX
Nome da EmpresaBlack Diamond Therapeutics Inc
Data de listagemJan 30, 2020
CEOVelleca (Mark A)
Número de funcionários24
Tipo de títulosOrdinary Share
Fim do ano fiscalJan 30
Endereço245 First Street, 18Th Floor
CidadeCAMBRIDGE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02142
Telefone16174175868
Sitehttps://www.blackdiamondtherapeutics.com/
Código da empresaBDTX
Data de listagemJan 30, 2020
CEOVelleca (Mark A)
Executivos da empresa Black Diamond Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
86.65K
+5208.00%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
+85150.00%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-20.00%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
31.03K
+4665.00%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Dr. Elizabeth Buck, Ph.D.
Dr. Elizabeth Buck, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Mr. Brent M. Hatzis-Schoch, Esq.
Mr. Brent M. Hatzis-Schoch, Esq.
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. Mark A. Velleca, M.D., Ph.D.
Dr. Mark A. Velleca, M.D., Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Ali Behbahani, M.D.
Dr. Ali Behbahani, M.D.
Independent Director
Independent Director
86.65K
+5208.00%
Ms. Erika Jones
Ms. Erika Jones
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
Senior Vice President - Finance, Principal Financial Officer and Principal Accounting Officer
85.15K
+85150.00%
Dr. Garry E. Menzel, Ph.D.
Dr. Garry E. Menzel, Ph.D.
Independent Director
Independent Director
76.64K
-20.00%
Dr. Prakash Raman, Ph.D.
Dr. Prakash Raman, Ph.D.
Independent Director
Independent Director
31.03K
+4665.00%
Dr. Kapil Dhingra, M.D.
Dr. Kapil Dhingra, M.D.
Independent Director
Independent Director
10.00K
--
Ms. Shannon Campbell
Ms. Shannon Campbell
Independent Director
Independent Director
8.87K
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sáb, 31 de jan
Atualizado em: sáb, 31 de jan
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
18.86%
Versant Ventures
10.89%
Vestal Point Capital, LP
9.74%
New Enterprise Associates (NEA)
7.81%
The Vanguard Group, Inc.
3.84%
Outro
48.86%
Investidores
Investidores
Proporção
T. Rowe Price Investment Management, Inc.
18.86%
Versant Ventures
10.89%
Vestal Point Capital, LP
9.74%
New Enterprise Associates (NEA)
7.81%
The Vanguard Group, Inc.
3.84%
Outro
48.86%
Tipos de investidores
Investidores
Proporção
Investment Advisor
30.59%
Investment Advisor/Hedge Fund
20.77%
Venture Capital
19.08%
Hedge Fund
7.72%
Research Firm
1.42%
Individual Investor
0.92%
Pension Fund
0.02%
Outro
19.48%
Participação acionária institucional
Atualizado em: seg, 8 de dez
Atualizado em: seg, 8 de dez
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
251
45.27M
104.04%
+4.70K
2025Q3
261
45.26M
106.75%
+270.69K
2025Q2
263
45.72M
119.11%
-2.33M
2025Q1
244
48.05M
134.35%
-28.07M
2024Q4
236
55.25M
127.86%
-855.91K
2024Q3
237
56.09M
121.86%
+1.99M
2024Q2
230
54.06M
101.77%
+8.09M
2024Q1
233
46.69M
117.14%
-13.89M
2023Q4
222
46.16M
104.70%
+1.30M
2023Q3
240
44.37M
104.97%
-4.12M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
T. Rowe Price Investment Management, Inc.
10.74M
18.86%
+231.97K
+2.21%
Sep 30, 2025
Versant Ventures
6.21M
10.89%
-221.60K
-3.45%
Apr 11, 2025
Vestal Point Capital, LP
5.55M
9.74%
-50.00K
-0.89%
Sep 30, 2025
New Enterprise Associates (NEA)
4.45M
7.81%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
2.19M
3.84%
+85.83K
+4.08%
Sep 30, 2025
Tang Capital Management, LLC
2.07M
3.63%
--
--
Sep 30, 2025
Marshall Wace LLP
1.30M
2.28%
+561.33K
+76.07%
Sep 30, 2025
Invus Public Equities Advisors, LLC
1.05M
1.84%
--
--
Sep 30, 2025
Arrowstreet Capital, Limited Partnership
896.85K
1.57%
+758.71K
+549.22%
Sep 30, 2025
Millennium Management LLC
850.33K
1.49%
-94.52K
-10.00%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Fidelity Enhanced Small Cap ETF
0.05%
iShares Micro-Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
DFA Dimensional US Small Cap Value ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Health Innovation Active ETF
0%
Vanguard US Momentum Factor ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Growth ETF
0%
Ver Mais
Fidelity Enhanced Small Cap ETF
Proporção0.05%
iShares Micro-Cap ETF
Proporção0.03%
Avantis US Small Cap Equity ETF
Proporção0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proporção0.01%
DFA Dimensional US Small Cap Value ETF
Proporção0%
iShares Russell 2000 Value ETF
Proporção0%
iShares Health Innovation Active ETF
Proporção0%
Vanguard US Momentum Factor ETF
Proporção0%
ProShares Hedge Replication ETF
Proporção0%
iShares Russell 2000 Growth ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
